MP-10-2
Life satisfaction in patients with erectile dysfunction D. Mallis, Greece; H. Grigoropoulos, D. Hatzichristou, K. Moisidis Introduction It is well accepted that the most significant outcome criterion in studies on erectile dysfunction (ED) is patients´satisfaction. Although satisfaction from sexual life has been extensively investigated, studies exploring the impact of ED in life satisfaction (LS) are lacking; the only available data are derived from quality of life questionnaires, which measure parameters that do not necessarily reflect LS. The aim of the study was to investigate the impact of ED in LS in a group of ED patients. Material and methods ED patients who attended an Andrologic Outpatient Clinic, completed the following questionnaires: 1) International Index of Erectile Function (IIEF) and, 2) Life Satisfaction Inventory (Greek version, LSI-Gr), in parallel with clinical evaluation by a psychiatrist. Results 69 male patients with ED (mean age 44) were included in the study. ED patients had statistically significant lower LSI total score (po0,01), low LSI-7 (Satisfaction from Sexual Life) score (po0,001), and high LSI-11 (Satisfaction from Hobbies) score (po0,001). IIEF and IIEF-5 scores correlated significantly with LSI-7 score, as well as with LSI-total score; however, IIEF could not predict LSI total score. Conlusions ED patients clearly experience a decrease in their satisfaction from life that is closely related to a remarkable fall in their satisfaction from sexual life, independently of the severity of ED. Patients may unconsciously mobilize several defense and/or coping mechanisms such as overinvolvement with other pleasurable activities (e.g.hobbies) in order to avoid psychiatric morbidity. As IIEF cannot predict LS, inclusion of a life satisfaction questionnaire may be mandatory in ED clinical outcome studies.
MP-10-3
Communication, initiative and effective treatment as determinants of sexual satisfaction in patients with ED and their partners M. Berne, Germany; J. Dieken, L. Kriston, U. Wetterauer
Background Erectile dysfunction produces high psychological forces for patients and their partners. In recent years many studies focused on the quality of life of patients. However, little data has been available on the partners and both their views on sexual relationship. We here report the results of a survey among the members of a nationwide patient association for sexual dysfunction (mainly ED). Methods In May 2002 a standardized questionnaire was sent out to the 1060 members of the association. It consisted of 2 identical parts (patient and partner) each containing 54 items. It covered the nature of sexual dysfunction, sexual satisfaction (from DSFI), sexual activity (from DSFI), and attitudes towards solving strategies for sexual problems. The response rate was 35,1%. 48,7% of members (patients) that did have a partner returned both questionnaires. Results Patients had a mean age of 63,2 7 12,0 (Partners: 58,8 7 11,2 years). 99,1% of Patients (Partners: 32,7%) indicated a sexual problem. 54,3% of Patients (Partners: 46,9%) stated that the sexual problem was a problem in their relationship. Patients were significantly less satisfied with their relationship than their Partners (po,001). Patients that had returned a partner questionnaire were significantly more satisfied in their sexual relationship (po,001) and indicated a better communication with their partners (po,001). The partnership satisfaction of patients and their partners was significatly higher for patients that had received sildenafil compared to those that did not have received any medication (po,05). Conclusion Our study adds some important information to the growing body of evidence that in patients with erectile dysfunction establishing a good communication, taking initiative in the partnership and receiving an effective treatment might be key determinants for sexual partnership satisfaction in both partners.
MP-10-4
Management of sexual dysfunctions in general practise: The patients' perspective R. Michieli, Italy; A. Sessa Sexuality is a basic aspect in people's psychological and physical development, which can strongly influence their perception of Quality of Life. Aim of this study is to verify, in the general practice setting , the knowledge of patients about sexual dysfunction (SD), their feeling about them, the prevalence of SD in the general practice population and the relation that occurs between patients and general practitioners (GPs) when a SD develops. A questionnaire of 13 questions was handed over to a randomized population of 40 GPs spread all over Italy, personally. All GPs explained the patients the aim of the questionnaire and asked them an anonymous restitution in closed envelope. We received 549 questionnaires back, 270 male and 279 female. 89% of the inquired population affirms to know what a SD is. From 29 to 35% of male and from 28 to 47% of female declares to suffer from SD. More than 82% in both sex says they have felt a sexual desire or stimulus during the last month, but 53,7% of male and 58,8% of female are actually little satisfied of their sexual life. 60,7% of patient would like to speak with their GP about their sexual problems, but 43,7% thinks that doctors should be more trained on this topic and that they should speak more frequently with their patients about sexual life. At the end only 10,9% of patients suffering from SD has already spoken with his GP about this. SD has a high prevalence in general practice but they are undervalued. A better knowledge and a higher skill in sexual counselling by GPs are needed to face problems that can influence people' Quality of Life.
MP-10-5
The effect of Sildenafil citrate on ejaculation latency time, detumescence period and second erection: A placebo controlled, double blind, cross-over in vitro study
Objectives To evaluate whether sildenafil citrate (SC) prolongs detumescence period, shortens the duration for second erection and, prolongs ejaculation latency time when vibratory stimulation is applied in an in vitro setting. Materials and method Two double blind, placebo controlled, crossover laboratory studies were performed with 30 different healthy volunteers in each study. In the first study, the subject ingested the placebo (P) or SC. Fifteen minutes later, real time penile tumescence and rigidity monitoring was performed. Fortyfive minutes following monitorisation, audiovisual sexual stimulation (AVSS) began. When the subject had his best erection he applied vibratory stimulation and put a mark. Vibration was continued till he ejaculated and put another mark and stopped AVSS. The monitorisation was continued till he had rigidity. The test was repeated with second medication in 7 to 15 days. In the second study other group was examined as same as in the first study. The difference was AVSS continued for another one hour following ejaculation. Results First Study Twentytwo men could participate in both placebo and drug arms. The results are shown in the Table 1 . Second study Twentytwo men could participate in both placebo and drug arms. The results are shown in the Table 2 .
Conclusion In this laboratory setting SC ssems to prolong ejaculation latency time. Detumescence time is longer and its quality is better. However, we could not show that SC shortens the duration of second erection following ejaculation.
MP-10-6
Tadalafil is effective for 36 hours in men with erectile dysfunction -Results from an 11 study integrated analysis D. Hatzichristou, Greece; S. Ahuja, J. Denne, J.-F. Eid, S. Whitaker
Objective Tadalafil, a phosphodiesterase-5 inhibitor, is an effective therapy for erectile dysfunction (ED). In an initial study, tadalafil improved erectile function for up to 36 hours after dosing. We conducted an integrated analysis of 11 studies to determine the efficacy of tadalafil in men with ED at all time points they chose to engage in sexual intercourse from 30 minutes to 36 hours after dosing. Design and Methods Doses of 10 mg (n¼321) and 20 mg (n¼1143) tadalafil and placebo (n¼638) were evaluated in 11 multi-center, randomized, double-blind 12-week efficacy studies. Medication was taken without restriction on time to intercourse attempt. A successful attempt was defined as a ''yes'' response to Question 3 of the Sexual Encounter Profile diary. Results The percent of successful intercourse attempts with 10 or 20 mg tadalafil was greater than placebo in all time intervals (Table) . Over 65% of intercourse attempts were successful between 1/2 to 1 hour, and 73.4% were successful as late as 24 to 36 hours after taking 20 mg tadalafil. Conclusions This integrated analysis shows the efficacy of 10 mg and 20 mg tadalafil in men with ED from 30 minutes to 36 hours postdosing. This broad window of therapeutic responsiveness can give men the freedom to choose when to attempt intercourse for up to 36 hours after taking tadalafil. Table) . The percent of men who achieved a Introduction The purpose of this study was to asses the effect of conventional and atypical antipsychotic agents in sexual and endocrine function in men. Participants and methods Twenty-five male participants with diagnosed schizophrenia according to DSMIV criteria entered the study. They all completed the IIEF questionnaire for erectile dysfunction. Serum prolactin, testosterone, estradiol, SHBG, FSH, LH, TSH were measured prior and during treatment with the conventional antipsychotics Haloperidol (group A; N¼7) and Zuclopenthixol (group B; N¼2) and the atypical antipsychotics Amisulpride (group C; N¼1), Clozapine (group D; N¼3), Olanzapine (group E; N¼3) and Risperidone (group F; N¼9), respectively. Results All patients receiving conventional and atypical antipsychotic treatment had IIEF scores between 6-10. Hyperprolactinaemia was present in all of the patients in group A, B, C, and in 8/9 (88.8%) of the patients in group F. Testosterone, SHBG, LH and FSH plasma levels were found within normal ranges in all patients. Estradiol was elevated in 2/3 (66.6%) of the patients in group D, in 2/3 (66.6%) of the patients in group E and in 6/9 (66.6%) of the patients in group F. TSH was decreased in 3/9 (33.3%) of the patients in group F. Conclusion Although in Olanzapine and Clozapine group the hormonal profiles were within normal levels, patients were still suffering from severe-moderate (IIEF scores between 7-10) sexual dysfunction. In some of the patients with sexual dysfunction during treatment with atypical antipsychotic drugs, the increase values of estradiol in serum may contribute to the etiology of sexual dysfunction. Hypothalamo-pituitary-gonadal axis is not clearly effected directly either from the conventionals or the atypical antipsychotics.
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MP-10-9
Intracavernous injections in the treatment of erectile dysfunction in spinal cord injured patients: 4 years experience with 83 patients B. Alici, Turkey; E. Akkus, H. Hattat, H. O¨zkara, D. Soy, M. Yelkovan
Objectives To determine the efficacy and long term results of intracavernous injections in the treatment of erectile dysfunction in spinal cord injured (SCI) patients. Design and methods This prospective study concerns 83 spinal cord injured men who were followed-up for 4 years. None of the patients had erectile dysfunction before the neurologic impairment. Sexual dysfunction was assessed by means of anamnesis, a specially developed questionnaire where the IIEF is not applicable, and neurological examination. The intracavernous injection was done with the papaverine with a starting dose of 7.5 mg. The injections were then repeated with increasing dosage to archive a sufficient (grade 4) or rigid (grade 5) erection for intercourse. If the erections were not sufficient, PGE1 and phentolamin injections were also used. Results The mean age of the patients was 35 years. The study group consisted of 80% paraplegics, 12% tetraplegics and 8% hemiparesics. 71 patients (85.5%) obtained an erection of grade 4 and 5. All patients started with intracavernosal injection therapy and 28 patients (39%) continued using intracavernosal injections at the end of 4 years. Papaverine was used by 20 patients and papaverine þ phentolamine by 5 patients and only 3 patients used Alprostadil. 3 patients had prolonged erections during the treatment (all within the first two months of treatment). 43 patients including the patients with prolonged erections preferred alternative treatment options. Conclusions Intracavernosal injections are efficient and because of its low cost, it's a preferred treatment option in SCI patients in Turkey.
MP-10-10
The effect of nasal pathology in patients with impotence and premature ejaculation Objective To investigate the effect of nasal pathology in patients with impotance and premature ejaculation. Material and Method A total of 19 patients with impotence (n¼9) and premature ejaculation (n¼10) divided into two groups. All this patients have been evoluated by anamnesis, nasal endoscopy, and ENT examination for nasal obstruction and sensetion of smell. A questionair involing 4 questions scored from 0 to 5 for evaluating subjective information about nasal obstruction and smell sense variations in their daily life and during intercourse has been performed all the patients by a otorhinolaryngolog. Results The mean age of the patients was 38 (range 25-52). Nasal pathologies have been found out in 5 and 8 patients out of 9 and 10 with impotence (I. Group) and premature ejaculation (II. Group), respectively. The complaint nasal obstruction has been noted in 3 and 5 patients in groups I and II respectively. The gradualtely increasing symptom of nasal obstruction, negatively effecting the patients, during to intercourse has been recorded in 1 (11%) and 4 (40%) patients in I and II groups respectively. While one patient complaint with hyposmia in group I, and two patients represented with hyposmia and anosmia in group II. Furthermore 2 (22%) patients in group II and 1 (10%) patient in group II have been reported bad smell sensation, 2 (20%) patients reported anosmia during intercourse. Discussion The effects of nasal pathologies such as nasal obstruction and smell sensetation on above mentioned Urologic disease have not investigated properly in the literature up to date. Conclusion: As result of this study, upper respiratory tract pathologies such as nasal obstruction and variations in smell sensetion have conversly effected the patients with impotence and premature ejaculation.
MP-10-11
Change in quality of life after radical prostatectomy I. Romics, Hungary; L. De´ry, L. Ka´llai, P. Riesz, A. Rusz
Introduction and Objectives The aim of this study was to evaluate the change in quality of life after radical prostatectomy with special attention to erectile function. Materials and methods 29 patients' case was evaluated, who underwent radical prostatectomy at our department and presented at all of 3 monthly visits until 12 months postoperatively. The mean age of patients was 60.6 year (range: 55-68, SD: 4.0). Mean follow up time was 16.5 months (range: 1-58). 60% of patients were hypertonic, 6.6% had ischaemic cardiac disease, 6.6%: diabetes and 6.6% rheumatoid arthritis. They all took appropriate medication. Otherwise patients were in good general condition, being candidates for such an upsetting surgical procedure. Nerve sparing procedure was tried to be performed in all cases. Erectile function before and after operation was evaluated by International Index of Erectile Function (IIEF). The quality of urinary continence was categorized in 3 groups: poor, medium, good due to the number and size of incontinence pads used by the patients. Results Preoperative erectile dysfunction: severe 7.1%, moderate 28.5%, no dysfunction in 64.2%. Postoperative results: severe 63%, moderate 21%, normal 15.8%. All patients had satisfactory urinary continence preoperatively. Postoperatively poor: 5%, medium: 15%, good: 80% was the distribution. Besides these, urethral stricture was the most frequent long-term complication: 15%. Conclusions To date, radical prostatectomy is the gold standard for definitive treatment of organ confined prostate cancer. Patients who underwent this procedure generally have good quality of life with few long-term complications. However, despite using nerve sparing operative techniques, postoperative erectile dysfunction remains a problem to be solved.
MP-10-12
Comorbidities and prostatic assessment in men with erectile dysfunction J. Silva, Portugal; M. Reis, N. Tomada, P. Vendeira Introduction and objectives Erectile dysfunction (ED) is a very prevalent disease and is a complex condition with organic and psychological factors in its aetiology. It is associated with chronic comorbidities and age. Also, benign prostatic hyperplasia (BPH), becomes more prevalent with increasing age, and the association between ED and BPH is not well understood. We investigated medical comorbidities, risk factors and prostatic evaluation in a population of patients with ED. Design and methods In a two-year period, 239 new patients with ED were admitted to our outpatient clinic. Patients were investigated about risk factors for ED, presence of other pathologies. A prostatic evaluation was made in 108 patients and hormonal study in 40. Results Mean age was 53,7712,2 years (21À78). The mean evolution time was 38,8742,6 months. 22,2% had mild ED, 54,8% moderate and 22,6% severe ED. Reduced ejaculation was referred by 7,9% of the patients and reduced libido by 9,6%. Comorbidities were very prevalent: arterial hypertension was present in 36,8% of patients, diabetes in 24,7%, hyperlipidaemia in 18%, cardiaovascular pathology in 12,1% and chronic renal failure in 2,9%. Cigarette smoking was observed in 37% of the patients and hormonal alterations were present in 12,5% of the population. Only 19,2% of the patients referred lower urinary tract symptoms (LUTS) and the mean prostate volume was 30,2715cc; mean total PSA was 1,3971,85ng/ml and post-void residual urine volume was insignificant. Conclusions Chronic comorbidities are very frequent in patients with ED. BPH and ED are correlated with age and is frequent the association of ED in patients with BPH. But, when we talk about patients with a primary complaint of ED, BPH and LUTS seems to be not so important.
